Basilea Pharmaceutica Ltd (XSWX:BSLN)
CHF 43.9 -0.25 (-0.57%) Market Cap: 526.94 Mil Enterprise Value: 595.65 Mil PE Ratio: 69.69 PB Ratio: 0 GF Score: 70/100

Full Year 2021 Basilea Pharmaceutica AG Earnings Call Transcript

Feb 15, 2022 / 03:00PM GMT
Release Date Price: CHF41.72 (+4.04%)
Operator

Ladies and gentlemen, welcome to the Basilea Pharmaceuticals Full Year Results 2021 Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. (Operator Instructions)

The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.

David Veitch
Basilea Pharmaceutica AG - CEO

Thank you very much. Hello, I'm David Veitch, CEO of Basilea, and I would like to welcome you to our conference call and webcast, reviewing our financial results and key achievements for the full year 2021 and in which we will be outlining our strategy for Basilea to become a leading global anti-infectives company.

For further detailed information, please see the ad hoc announcement issued this morning and also our financial report 2021. These documents are both available on our website at basilea.com. I would also like to mention that this call contains forward-looking statements. Joining me on our call today are Adesh Kaul, our Chief Financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot